# OPPORTUNISTIC SCREENING FOR HYPERTENSION IN THE GENERAL POPULATION IN BULGARIA: INTERNATIONAL SOCIETY OF HYPERTENSION MAY MEASUREMENT MONTH CAMPAIGN 

A. Postadzhiyan ${ }^{1,7}$, Y. Yotov ${ }^{2}$, S. Tisheva-Gospodinova ${ }^{3}$, F. Nikolov ${ }^{4}$, K. Ramshev ${ }^{5}$, I. Gruev ${ }^{6}$, D. Raev ${ }^{7}$<br>${ }^{1}$ Medical University, Sofia, Saint Anna University Hospital, Hypertension Excellence Centre - Sofia, Bulgaria ${ }^{2}$ Medical University - Varna, Bulgaria<br>${ }^{3}$ Medical University - Pleven, Bulgaria<br>${ }^{4}$ Medical University - Plovdiv, Bulgaria<br>${ }^{5}$ Military Medical Academy - Sofia, Bulgaria<br>${ }^{6}$ National Multiprofile Transport Hospital Tsar Boris - Sofia, Bulgaria<br>${ }^{7}$ Saint Anna University Hospital, Hypertension Excellence Centre - Sofia, Bulgaria

# ОПОРТЮНИСТИЧЕН СКРИНИНГ ЗА ХИПЕРТОНИЯ СРЕД ОБЩО НАСЕЛЕНИЕ В БЪЛГАРИЯ: КАМПАНИЯ МАЙ МЕСЕЦ ЗА МЕРЕНЕ НА МЕЖДУНАРОДНОТО ДРУЖЕСТВО ПО ХИПЕРТОНИЯ 

А. Постаджиян ${ }^{17}$, Й. Йотов², С. Тишева-Господинова ${ }^{3}$, Ф. Николов ${ }^{4}$, К. Рамшев ${ }^{5}$, И. Груев ${ }^{6}$, Д. Раев ${ }^{7}$<br>${ }^{1}$ Медицински университет - София<br>${ }^{2}$ Медицински университет - Варна<br>${ }^{3}$ Медицински университет - Плевен<br>${ }^{4}$ Медицински университет - Пловдив<br>${ }^{5}$ ВМА - София<br>${ }^{6}$ Многопрофилна транспортна болница Цар Борис - София<br>ТУМБАЛ Света Анна - София


#### Abstract

Cardiovascular diseases are not only the leading causes of mortality in Bulgaria but also the mortality rate is twice as high as the European Union average, so screening programmes identifying subjects with elevated blood pressure (BP) are of utmost importance. May Measurement Month (MMM) is an annual global initiative of the International Society of hypertension that began in 2017 aimed at raising awareness of high BP. Bulgaria joined the 3rd campaign of MMM in 2019 and an overview of the results of Bulgarian participation are presented in this paper. Hypertension was defined as systolic BP $\geq 140 \mathrm{~mm} \mathrm{Hg}$ and diastolic BP $\geq 90 \mathrm{~mm} \mathrm{Hg}$ or treatment for hypertension, statistical analysis followed the standard MMM protocol. In Bulgaria, 150 screening points were set up in primary and secondary care facilities, in pharmacies, and outdoor spaces across 21 administrative districts. Out of 3678 individuals screened, 2587 participants ( $70.3 \%$ ) had hypertension. Of 2896 participants with hypertension, $35.6 \%$ had controlled BP. Out of 1760 participants not on antihypertensive medication, $669(38 \%)$ had elevated BP. In the case of treated individuals ( $\mathrm{n}=1918$ ), 997 ( $52 \%$ ) had uncontrolled hypertension. In the untreated cohort, every 4th subject had elevated BP, whilst among patients on antihypertensive medication, every second had uncontrolled BP, the worst results in terms of diagnosis and treatment are observed in men. By identifying almost two-third of the whole screened cohort with the possibility of newly diagnosed or uncontrolled hypertension, our results confirm the importance of BP screening campaigns.


Key words: Hypertension, Blood Pressure, Screening. Treatment, Control, Bulgaria

Address for correspondce:

Prof. A. Postadzhiyan, PhD, Department of cardiology, Saint Anna University Hospital, 1 D. Mollov str, Sofia 1784, Bulgaria, e-mail: armanp@abv.bg

Резюме. Сърдечно-съдовите заболявания са не само водеща причина за смъртността в България, но и смъртността е два пъти по-висока от средната за Европейския съюз, така че скрининговите програми, идентифициращи лица с повишено артериално налягане (АН), са от изключително значение. Май Месец на Мерене (МММ) представлява годишна глобална инициатива на Международното дружество по хипертония, която започна през 2017 г. и има за цел да

[^0]повиши осведомеността за високото артериално налягане. България се присъедини към 3-та кампания на МММ през 2019 г. и в настоящата публикация е представен преглед на резултатите от българското участие. Хипертонията се дефинира като систолно $\mathrm{AH} \geq 140 \mathrm{~mm} \mathrm{Hg}$ и диастолно $\mathrm{AH} \geq 90 \mathrm{~mm} \mathrm{Hg}$ или провеждано лечение за хипертония, статистическият анализ следва стандартния протокол МММ. В България бяха създадени 150 пункта за скрининг в първична и вторична медицинска помощ, в аптеки и на открити пространства в 21 административни области. От 3678 скринирани лица, хипертония установяваме при 2587 участници (70,3\%). Сред тях, 35,6\% са с контролирано артериално налягане. От 1760 участници, които не са на антихипертензивно лечение, повишено АН установяваме при 669 (38\%). В случай на лекувани лица ( $n=1918$ ), 997 (52\%) имат неконтролирана хипертония. В нелекуваната кохорта всеки 4-ти субект е с повишено АН, докато сред пациентите на антихипертензивно лечение всеки втори има неконтролирано AH , като най-лоши резултати по отношение на диагнозата и лечението се наблюдават при мъжете. Чрез идентифициране на почти две трети от цялата изследвана кохорта с възможност за новодиагностицирана или неконтролирана хипертония, нашите резултати потвърждават важността на кампаниите за скрининг на АН.

| Ключови думи: | Хипертония, артериално налягане, скрининг, лечение, контрол, България |
| :--- | :--- |
| Адрес | Проф. А. Постаджиян, дм, Клиника по кардиология, УМБАЛ Света Анна, ул. Д. Моллов № 1, София 1784 Бълга- |
| за кореспонденция: | рия, e-mail - armanp@abv.bg |

## Introduction

Despite sustained declines in cardiovascular disease (CVD) mortality in many countries across Europe, it remains the most common cause of death within the region [1]. According the data on e-atlas of European Society of Cardiology four of the 13 middle-income countries demonstrated an increase in crude premature mortality (deaths under the age of 70 years) rates from 2010 to the most recent year of data in females (Bulgaria, Egypt, Republic of Georgia and Turkey) and six did so in males (Bulgaria, Egypt, Republic of Georgia, Romania, Serbia and Turkey) [2]. Overall life expectancy at birth in Bulgaria temporarily fell by 1.5 years in 2020 compared to 2019, largely due to the high number of deaths from the COVID-19 pandemic. Stroke (number of death 20687; 19.3\%), ischemic heart disease (12101, 11.3\%) and lung cancer (3341; $3.1 \%$ ) are the leading causes of death and accounted for one third of all deaths in 2018 in the county [3].

The early diagnosis and the proper treatment of hypertension, as a major contributor to CVD mortality merits a high priority to improve the CV outcome of the Bulgarian citizens. That is why the Bulgarian Hypertension League had decided in 2019 to join May Measurement Month (MMM), the hypertension awareness campaign from the International Society of Hy pertension (ISH) [4]. In light of the clear inadequacies of BP screening and management facilities around the world, MMM provides an inexpensive and pragmatic temporary solution to identifying individuals in need of improved hypertension care, whilst also raising awareness of the importance of BP measurement at the population level. Ultimately, the data generated are intended to inform and persuade governments and health policymakers to improve BP screening and management facilities and thereby reduce the enormous global
health burden caused by raised BP. 1 This publication provides the data of the first participation of Bulgaria in the global initiative.

## Material and methods

The May Measurement Month initiative of the International Society of Hypertension is lead globally by prof. Neil Poulter [4-5]. MMM is a cross-sectional survey of any adults ( $\geq 18$ years) who wished to have their BPs measured at any of the MMM screening sites. These sites were set up by volunteer investigators who followed a common protocol (available on the MMM website: www. maymeasure.com). Ideally, by design, the survey sought out those who had not had their BP measured for at least a year, but no adults were excluded from the study. Training materials, critically including standardized BP measurement techniques and campaign promotional materials were made available via the MMM website. Those presenting for BP measurement, who gave informed consent to participate, provided data collected on a simple questionnaire, including demography and medical history and where facilities allowed, weight and height were measured and recorded. Hypertension was defined primarily as a systolic $B P \geq 140 \mathrm{~mm} \mathrm{Hg}$ or a diastolic $B P \geq 90 \mathrm{~mm} \mathrm{Hg}$ [6-7] using the mean of the second and third BP readings or being on treatment with antihypertensive medication(s). Hypertension based on the definition used in the most recent US guidelines ( $\geq 130 / 80 \mathrm{~mm} \mathrm{Hg}$ ) was also evaluated [8].

MMM 2019 in Bulgaria was organized by the Bulgarian Hypertension League. Altogether 150 screening points in 21 of 28 administrative districts were involved in MMM Bulgaria 19 campaign. Medical students and trained physicians performed triplicate sitting BP measurements using validated
upperarm oscillometric devices OMRON M7 Intelli IT AFib ( $n=1603$ ) and Microlife WatchBP Office BP monitor ( $n=2075$ ). Individuals with HTN or uncontrolled BP were provided with printed dietary and lifestyle advice and recommendations to visit their GP or dedicated hypertension centers. Collected data were analyzed centrally by the MMM project team and multiple imputation was performed to impute the mean of the $2 n d$ and 3 rd readings where they were missing. Statistical analysis was performed using SPSS Statistics 19. Chi-square tests and analysis of variance was used for categorical and continuous variables, respectively. Analysis of measures of association used only those individuals with complete data on age, sex, ethnicity, and use of antihypertensive medication. Linear mixed-effects models were run separately for systolic and diastolic BP, assuming a random intercept model to account for country level clustering effects. It was decided a priori to adjust for age, sex, and antihypertensive medication, along with an interaction between age and sex, given the known strong effects of these variables on BP.

## Results

In total, 3678 first time participating in MMM campaign Caucasian individuals were screened. Despite the fact that 2516 (71.2\%) of them had their last BP measurement within 12 months, 212 (6\%) reported never having had BP measured. The mean age of screened participants was 58.8 ( $\mathrm{SD} \pm 16.6$ ) years, $62.8 \%$ were female, among them $2.1 \%$ reported a history of hypertension in a previous pregnancy. The characteristics for all participants are given in table 1, together with a comparison of the data from the global MMM 2019 publication. Of all screened, 11.5\% reported having diabetes mellitus (either type I or type II),
13.8\% a history of myocardial infarction, 6.4\% a history of stroke, $20.3 \%$ were current smokers, and $20 \%$ reported drinking alcohol at least once per week. The mean BMI was $26.4 \mathrm{~kg} / \mathrm{m}^{2}$ (SD 6.04) in women and $28.1 \mathrm{~kg} / \mathrm{m}^{2}$ (SD 10.1) in men. 675 (35.2\%) women and 472 (42.9\%) men were overweight, and 421 (22\%) women and 281 ( $25.5 \%$ ) men were obese.

Based on the inclusion criteria, all participants had at least one BP reading and 2637 (71.7\%) had all 3 BP readings recorded. Analysis of only those with all three readings showed that BP fell, on average, by $2.4 / 3 \mathrm{~mm} \mathrm{Hg}$, from a mean of $135.2 / 83.5 \mathrm{~mm}$ Hg for the first reading to a mean of $132.8 / 80.5 \mathrm{~mm}$ Hg for the third reading. The mean BP (based on individuals with the second and third $B P$ reading available) was $135.2 / 82.3 \mathrm{~mm} \mathrm{Hg}$ before and 133.7/81.5 mm Hg after age and sex standardization. In those patients who were not on antihypertensive medication, the mean BP was $131 / 81.3 \mathrm{~mm} \mathrm{Hg}$, while in those, who were on antihypertensive medication, it was $136.8 / 82.7 \mathrm{~mm} \mathrm{Hg}$.

Following imputation, of all 3678 participants, 2587 (70.3\%) had hypertension (Table 2). Of those with hypertension, $73.8 \%$ were aware of their diagnosis, and $74.1 \%$ were on antihypertensive medication. Of the 1918 participants on medication, 921 ( $48 \%$ ) had a BP controlled to $<140 / 90 \mathrm{~mm} \mathrm{Hg}$ and 370 (19.3\%) controlled to $<130 / 80 \mathrm{~mm} \mathrm{Hg}$. Of all hypertensive participants, $35.6 \%$ were controlled to $<140 / 90 \mathrm{~mm} \mathrm{Hg}$ and $14.3 \%$ to $<130 / 80 \mathrm{~mm} \mathrm{Hg}$. Of those participants not taking antihypertensive medication, 669 ( $38 \%$ ) were found to have hypertension. The highest proportion of untreated (50.6\%) and inadequately treated hypertension (58.6\%) were noticed in male participants in the campaign, the corresponding percentages in females were $29 \%$ and $48.7 \%$ respectively (table 3 ).

Table 1. Participants characteristics in Bulgaria and globally in MMM 2019

|  | Bulgaria <br> MMM 2019 | Worldwide <br> MMM 2019 | Bulgaria <br> MMM 2019 <br> 40-50 years |
| :--- | :---: | :---: | :---: |
| Age | $58.82 \pm 16.6$ | $45.3 \pm 17$ | $40-50$ |
| Female sex | 62.8 | 51.4 | 58.6 |
| Smoking | 20.3 | 13.7 | 31.8 |
| Alcohol at least 1 week | 20 | 6.4 | 22.3 |
| Diabetes | 11.5 | 9 | 9.6 |
| Overweight | 38.7 | 30.8 | 34.9 |
| Obesity | 23.3 | 14.4 | 21.9 |
| On antihypertensive medications | 52.1 | 20.4 | 39.3 |
| Previous infarction | 13.8 | 4.2 | 8.4 |
| Previous stroke | 6.4 | 2.8 | 6.6 |

Table 2. Total participants and proportions with hypertension, awareness, on medication and with controlled BP

|  | Number (\%) with <br> hypertension | Number (\%) of <br> hypertensives <br> aware | Number (\%) of <br> hypertensives on <br> medication | Number (\%) of those <br> on medication with <br> controlled BP | Number (\%) of all <br> hypertensives with <br> controlled BP |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Total participants <br> 3678 | $2587(70.3 \%)$ | $1910(73.8 \%)$ | $1918(74.1 \%)$ | $921(48 \%)$ | $921(35.6 \%)$ |
| Female <br> 2309 | $1580(68.4 \%)$ | $1256(79.5 \%)$ | $1282(81.1 \%)$ | $658(51.3 \%)$ | $658(41.6 \%)$ |
| Male <br> 1369 | $1100(73.6 \%)$ | $654(64.9 \%)$ | $636(63.2 \%)$ | $263(41.4 \%)$ | $263(26.1 \%)$ |

Table 3. Untreated and inadequately treated hypertension according to sex

|  | Number (\%) with <br> hypertension | Number (\%) of participants with hypertension of <br> those not on antihypertensive medications | Number (\%) of participants with <br> uncontrolled BP of those on medication |
| :--- | :---: | :---: | :---: |
| Total participants <br> 3678 | $2587(70.3 \%)$ | $669(38 \%)$ | $997(52 \%)$ |
| Female <br> 2309 | $1580(68.4 \%)$ | $298(29 \%)$ | $624(48.7 \%)$ |
| Male <br> 1369 | $1100(73.6 \%)$ | $371(50.6 \%)$ | $373(58.6 \%)$ |

In general, 1918 (52.1\%) participants were taking antihypertensive medication, and of the 1546 with a recorded number of medication classes, $40.2 \%$ were taking a single medication, and $34.3 \%, 17.8 \%$, and $6.5 \%$ were taking 2 , 3 , and 4 , respectively. Only $1.2 \%$ were taking $\geq 5$ antihypertensive drugs. In participants taking a single antihypertensive medication, 50.2\% were uncontrolled, and in those taking 2 drug classes, 49\% were uncontrolled. Proportions with uncontrolled BP were similar in those on 3 (49.8\%) and higher in those on 4 ( $56.0 \%$ ) or $\geq 5$ ( $83.3 \%$ ) medications. In total, 255 participants were defined as treatment-resistant, which is $16.5 \%$ of the hypertensive population included in the study for whom data on the number of medications were available. The proportion of treatment-resistant participants fell down to $13.4 \%$ if the definition excludes the patients with controlled BP of more than 4 medications.

Based on linear mixed models, mean systolic BP displayed a roughly linear increase with age in both men and women who were not using antihypertensive medication (Figure 1). In contrast, mean diastolic BP showed an inverted U-shaped curve, with BP peaking at 50 to 55 years and then gradually decreasing. Systolic BP was higher in males compared to females until the age of about 70 years, after which the mean systolic was higher in females. Similarly, diastolic BP was higher in males until 70 years, after which there were no significant differences between the sexes.

Of all risk factors analyzed, reported use of antihypertensive medication and a previous diagnosis of hypertension were the strongest predictors of high-
er levels of systolic and diastolic BP. After adjusting for age and sex, participants taking antihypertensive medication had a higher mean systolic BP ( 4.9 mm Hg higher, $\mathrm{P}<0.001$ ) and higher diastolic $\mathrm{BP}(1.4 \mathrm{~mm}$ Hg higher, $\mathrm{P}<0.001$ ) compared with those not taking medication (Figure 2). After adjusting for age, sex, and antihypertensive medication use, those with known hypertension had a significantly higher mean systolic ( 5.8 mm Hg higher, $\mathrm{P}<0.001$ ) and diastolic BP (1.7 mm Hg higher, $\mathrm{P}<0.001$ ) compared with those without known hypertension. BMI was also strongly linked to both systolic and diastolic BP, with a linear increase in both with increasing BMI category. The difference in mean systolic and diastolic BP in those participants with a BMI in the obese range, compared with those of healthy weight was 39 mm Hg and 2.4 mm Hg , respectively (Figure 3).

Several smaller but significant differences in systolic and diastolic BP were observed in association with several conditions or risk factors. For example, participants with a history of myocardial infarction or stroke had significantly higher systolic BPs, but significantly lower diastolic BPs (Figure 2). In addition, a significant dose-dependent increase in both systolic and diastolic BP was seen in alcohol drinkers compared with nondrinkers, after adjusting for age, sex, and antihypertensive medication use (Figure 3). Participants who currently smoked had a small, but statistically significant increase in diastolic BP. Conversely, participants, compliant with regular physical activity ( 150 mins of moderate exercise or 75 mins of more vigorous exercise per week) had significantly lower systolic and diastolic BPs than those who were not.



Fig. 1. Mean systolic and blood pressure by age and sex from linear mixed models, in participants not taking antihypertensive medication


Fig. 2. Difference in mean systolic and diastolic blood pressure ( BP ; with $95 \% \mathrm{CI}$ ) in those with each condition compared to those without, from linear mixed models adjusted for age, sex, and antihypertensive medication. Antihypertensive medication adjusted for age and sex only.


Fig. 3. Difference in mean systolic and diastolic blood pressure (BP; with $95 \% \mathrm{CI}$ ) in those with each condition compared to those without, from linear mixed models adjusted for age, sex, and antihypertensive medication

## DIscussion

With 3678 participants, the MMM19 was the first participation of Bulgaria in the global MMM imitative of the International Society of Hypertension and the largest BP screening campaign in the country. More than half of the whole cohort had hypertension (treated or untreated). Every 4th untreated participant had elevated BP and almost every 2nd participant taking antihypertensive therapy had uncontrolled BP. We identified

684 subjects with possible undiagnosed HTN and 1140 inadequately treated subjects, which represents a total of $64.4 \%$ of the screened cohort. Men had lower rates of hypertension diagnosis and control than women, and young individuals lower than older ones. Strong positive associations were seen between BP and risk factors, such as increasing BMI and increasing alcohol intake. Patients with a history of myocardial infarction or previous stroke had a significantly higher level of systolic, but lower level of diastolic blood pressure. The
comparison of the risk profile in Bulgaria with that of the published data from the global initiative enables the establishment of important differences. At a relatively early age, between 40-50 years old, we find a reliably higher burden of all risk factors in Bulgaria - smoking, arterial hypertension, overweight, etc. As a result, cardiovascular events experienced are almost double those found in this age group globally. A half of treated hypertensive were on monotherapy and concomitant use of lipid lowering therapy was less than $30 \%$, especially in patient population without cardiovascular disease. These findings suggest high level of medical inertia and poor patient adherence in intensifying treatment for achieving optimal control. Due to methodological limitations and opportunistic sampling, as well as higher age of individuals the sample cannot be considered representative of the entire Bulgarian population. Nevertheless, this is a large sample and obtained data are in line with reports from other European populations and with the available epidemiological studies conducted in the country [9-12].

In conclusion, there is considerable potential for improving the control of hypertension in the general population in Bulgaria. The MMM data should be used to press healthcare policymakers for implementing health campaigns and screening programmes at population level, and specifically targeted working-age individuals and men in whom undiagnosed hypertension is more common. Training programmes are also needed for practicing doctors to help to improve patient compliance and intensify the treatment of hypertension and other cardiovascular risk factors until optimal control is achieved.

Acknowledgments: Sincere thanks to many volunteer investigators, Bulgarian Hypertension League staff, the Association of Medical Students in Bulgaria, Bulgarian Red Cross, DINI OTC, National Fondation Heart for heart and all participants.

[^1]
## References

1. Global Burden of Disease Website. Institute for Health Metrics and Evaluation. http://vizhub.healt hdata.org/gbd-compa re/.
2. European Heart Network. European Cardiovascular Disease Statistics 2017 edition. http://www.ehnheart.org/cvd-statistics/ cvd-statistics-2017.html
3. OECD/European Observatory on Health Systems and Policies (2021), Bulgaria: Country Health Profile 2021, State of Health in the EU, OECD Publishing, Paris, https://doi.org/10.1787/c1a721b0en.
4. Beaney T, Schutte AE, Stergiou GS et al, on behalf of MMM investigators. May Measurement Month 2019. Hypertension 2020;76:333-341.
5. Beaney T, Burrell LM, Castillo RR et al. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J. 2019;40:2006-2017. doi: 10.1093/eurheartj/ehz300
6. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104. doi: 10.1093/eurheartj/ehy339
7. National Institute for Health and Clinical Excellence, Hypertension (NG136): clinical management of primary hypertension in adults. https:// www.nice.org.uk/guidance/ng136. Accessed September 28, 2019.
8. Whelton PK, Carey RM, Aronow WS et al. ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines 2017. Hypertension. 2018;71:1269-1324. doi:10.1161/ HYP. 0000000000000066
9. Yotov YT, Torbova SV, Naydenov S et al. Risk Factors for cardiovascular diseases in urban population with arterial hypertension - have they changed in five years in Bulgaria? Abstract P3237. Eur Heart J 2013; 34 (Abstract Suppl): 598-599
10. Yotov Y, Torbova S, Naydenov S et al. Prevalence, awareness, and control of arterial hypertension in Bulgarian urban population - comparative epidemiologic study 2007-2012. 23rd European Meeting on Hypertension and Cardiovascular Protection, 14-17 June 2013, Milan, Italy. PP.16.15. J Hypertens 2013; 31 (e-Suppl A): e286
11. Raev D, Barkalova D. Initial therapy of arterial hypertonia in Bulgaria - results of a nationwide, prospective observational registry. Bulgarian Cardiology, 2015, 1: 30-35.
12. Postadzhiyan A. Yotov Y, Tisheva S et al. Incident atrial fibrillation and thrombo-embolic risk-a report from may measurement month 2019 screening programme in Bulgaria. Journal of Hypertension 2022; 40(Suppl 1): e128.

[^0]:    This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

[^1]:    Не е деклариран конфликт на интереси

